Clinical Research Directory

Vascular Effects of SGLT2i in Non-diabetic CKD

Sponsor: VA Office of Research and Development

Summary

Empagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), is a novel diabetic medication that reduces the risk of progression of chronic kidney disease (CKD) and heart failure and improves exercise tolerance regardless of the diabetes status. One of the important ways that empagliflozin improves health may be through its benefits on blood vessels. The effects of empagliflozin on blood vessels and physical function have not been examined in patients with chronic kidney disease, and it is less clear if empagliflozin may be beneficial in patients with chronic kidney disease without heavy urinary protein leakage. The investigators will examine if empagliflozin can improve blood vessel function and exercise tolerance in Veterans with chronic kidney disease without heavy urinary protein leakage.

Official title: The Effects of SGLT2 Inhibition on Vascular Health and Physical Function in Veterans With CKD

Key Details

Conditions

Interventions

Locations (1)